The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the investigational new drug (IND)-enabling and early-stage development of medications to treat alcohol use disorder (AUD) and alcohol-associated organ damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with robust background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The research objectives include pre-clinical development, IND-enabling toxicology, clinical development, and small early-phase clinical trials. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. For more information, visit the solicitation agency URL: link.